ASCO 2012 Lung Cancer Highlights: Dr. Socinski on Continuation Maintenance Alimta in PARAMOUNT Trial

Article and Video CATEGORIES

Cancer Journey

ABOUT

Howard Jack West, MD, Founder, Board President

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

ASCO 2012 Lung Cancer Highlights: Dr. Socinski on Continuation Maintenance Alimta in PARAMOUNT Trial

Dr West

Sat, 08/18/2012 - 12:11

Author

Howard (Jack) West, MD

The first of several podcasts we'll be adding here from our ASCO 2012 Lung Cancer Highlights program, co-sponsored with LUNGevity Foundation, is with Dr. Mark Socinski, Professor at the University of Pittsburgh, who discussed the updated results of continuation maintenance therapy with Alimta (pemetrexed) on the PARAMOUNT trial. Here is his summary of the presentation that now includes data on the overall survival in that study, which demonstrated a significant benefit for the recipients of continuation maintenance Alimta.

Dr. Socinski ASCO LC Highlights PARAMOUNT Trial Audio Podcast

Dr. Socinski ASCO LC Highlights 2012 PARAMOUNT Trial Transcript

Dr. Socinski ASCO LC Highlights 2012 PARAMOUNT Trial Figs

We'll turn out the podcasts from this program in rapid succession. Look for the next one, with Dr. Socinski reviewing an important trial on poor performance status patients with advanced NSCLC, very soon.

Next Previous link

Previous Post Next Post

Article

Las biopsias líquidas están revolucionando la forma en que combatimos el cáncer, ofreciendo un futuro donde la detección y el tratamiento son más rápidos, precisos y menos invasivos.

Videoteca de Cáncer de Pulmón en Español 2025

Video

Como parte de la Videoteca de Cáncer de Pulmón en Español 2025, oncólogos expertos discuten las opciones de tratamiento y la información más emergente en cáncer de pulmón. El Dr. Raez aborda la terapia para cánceres de pulmón EGFR y ALK, además de analizar otros tres temas de actualidad. La Dra. Viola y la Dra. Riaño también contribuyen a esta videoteca, cada una presentando tres temas relevantes sobre el cáncer de pulmón.

Unlocking Precision in Lung Cancer: Understanding and Overcoming Resistance to EGFR and ALK Inhibitors

Article

The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.